Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin versus ofloxacin or fortified tobramycin/cephazolin for bacterial keratitis
ACTRN12606000406505Phase 3Completed
- Sponsor
- Centre for Eye Research Australia
- Start
- Oct 2002
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of moxifloxacin, ofloxacin, tobramycin and cefazolin in bacterial keratitis (3 arms), sponsored by Centre for Eye Research Australia. Primary endpoint: Primary efficacy and safety assessment. Started Oct 2002; status: completed.
02
Drugs
moxifloxacinofloxacintobramycincefazolin
03
Conditions
bacterial keratitis
Beyond the preview
Go deeper on ACTRN12606000406505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000406505.